REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
We remain confident that REDUVO shall receive a Notice of Compliance (NoC) from Health Canada in the coming months.
- We remain confident that REDUVO shall receive a Notice of Compliance (NoC) from Health Canada in the coming months.
- REDUVO willhelp us create ourCanadianfootprint with healthcare professionalstoestablishour leading position in cannabinoid-derived medicines."
- REDUVO will pave the way for the global drug launch of REDUVO Adversa in 2024, a dronabinol administered product through an innovative mucoadhesive tablet delivery system, including patent protection.
- REDUVO Adversa cumulative global gross sales are expected to reach $79M by 2026.